Chinese Journal of Pharmacovigilance ›› 2018, Vol. 15 ›› Issue (1): 20-23.
Previous Articles Next Articles
YAN Ruo-xi, CAO Yi*
Received:
2018-02-12
Revised:
2018-02-12
Online:
2018-01-20
Published:
2018-02-12
CLC Number:
YAN Ruo-xi, CAO Yi. Analysis of Data Integrity Defects in Drug Manccfacturers[J]. Chinese Journal of Pharmacovigilance, 2018, 15(1): 20-23.
[1] IPA. Data Reliability Guideline[S/OL]. (2017-02-10)[2017-09-01].http://www.ipapharma.org/news/ data-reliability-guideline. [2] PIC/S. Good Practices For Data Management And Integrity In Regulated GMP/GDP Environments[S/OL]. (2015-05-26)[2017-09-01].https://picscheme.org/en/publications?tri=draft. [3] MHRA. GxP Data Integrity Definitions and Guidance for Industry[S/OL]. (2016-07-21)[2017-09-01]. https://www.gov.uk/government/news/mhra-gxp-data-integrity-definitions-and-guidance-for-industry [4] PDA. Points to Consider Elements of a Code of Conduct for Data Integrity[S/OL]. (2016-07-19)[2017-09-01].http://www.pda.org/scientific-and-regulatory-affairs/regulatory-resources/data-integrity. [5] 郑平. 在药品生产质量关体系中的数据完整性[D].上海交通大学硕士学位论文, 2015:1. [6] 李泮海,李进启,范秋英,等. 药品生产企业质量管理理念发展探讨[J]. 中国药物警戒,2011,8(2):93. [7] CFDA.GMP附录:计算机系统[S/OL]. (2015-05-26)[2017-09-01]. http://www.sda.gov.cn/WS01/CL0087/120500.html. [8] CFDA.药品数据管理规范(征求意见稿)[S/OL]. (2017-08-25)[2017-09-01]. http://www.sda.gov.cn/WS01/ CL0778/176732.html. [9] WHO. Guidance on good data and record management practices[S/OL]. (2016-05-01)[2017-09-01].http://www.who.int/medicines/publications/pharmprep/WHO_TRS_996_annex05.pdf?ua=1. [10] 国家食品药品监督管理总局食品药品审核查验中心.2016年度药品检查报告[S/OL]. (2017-06-02)[2017-09-01].http://www.cfdi.org.cn/resource/news/2016pdf_ch.html. |
[1] | JIA Jinsheng, LIU Hongliang, WANG Qing, HOU Yongfang, LI Xinling. Evaluation of the relevance of adverse drug reaction based on ERNIE-DPCNN [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 163-166. |
[2] | MA Meiying, ZHAO Xiaopei, ZHANG Mengyao, HU Yilin. Drug traceability coding system in China [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 167-172. |
[3] | ZHU Ying, SHEN Lu, LI Lan, WU Jianmin, GAO Xiaojie. Adverse reaction monitoring of toothpaste in China under the new regulatory system [J]. Chinese Journal of Pharmacovigilance, 2024, 21(2): 219-222. |
[4] | GAO Yunjuan, ZHAO Xu, BAI Tiankai, BAI Zhaofang, WANG Jiabo, SONG Haibo, XIAO Xiaohe. Discovery and identification strategy for drug safety risks based on big data monitoring of adverse reactions [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 1-5. |
[5] | MA Li’na, HU Xiaozhen, ZHENG Changhui, SUN Ying, ZHAO Xu, CAO Junling, XIAO Xiaohe. Visual analysis of knowledge map of toxic Chinese medicine Changshan toxicity-effect transformation based the thought of “yin du wei neng” [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 25-32. |
[6] | LIU Min, CHEN Yan, LIU Wendong, WANG Haixue. Updates and reflections on expedited reporting of safety information during drug clinical trials [J]. Chinese Journal of Pharmacovigilance, 2024, 21(1): 98-101. |
[7] | TIAN Chunhua, WU Guizhi. Implementation of periodic benefit risk evaluation reports in China [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1382-1384. |
[8] | ZHAO Yan, LI Yao, SONG Ya’na, ZHENG Lijia, LI Dong, ZHAO Yifei, BIAN Rongrong, DONG Fang. Post-marketing active monitoring of medical devices under vigilance [J]. Chinese Journal of Pharmacovigilance, 2023, 20(12): 1385-1390. |
[9] | PANG Yu, LIU Bo, WU Wenyu, TIAN Yuejie, WANG Tao. Establishment of patient reporting scheme in the UK and its implications [J]. Chinese Journal of Pharmacovigilance, 2023, 20(11): 1259-1263. |
[10] | WU Yunxiao, YU Yuelin, WANG Shengfeng, SUN Feng, MENG Ruogu, ZHAN Siyan. Suitability assessment of real-world data in active post-marketing surveillance of vaccine safety [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1081-1089. |
[11] | JIA Jinsheng, WANG Qing, LIU Hongliang, HOU Yongfang. Evaluation index system of MAH pharmacovigilance work [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1090-1094. |
[12] | LIU Hongliang, WANG Qing, HOU Yongfang. Design and implementation of polypharmacy risk data management platform for common diseases of the elderly based on real world data [J]. Chinese Journal of Pharmacovigilance, 2023, 20(10): 1095-1098. |
[13] | XIA Xudong, LI Meixia, SUN Yang, YANG Shengya. Processes of remote inspection of pharmacovigilance for marketing authorization holders [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 967-970. |
[14] | LI Xiaozhu, WANG Qiang, PANG Yu, ZHANG Yijing. Management of individual adverse drug reaction reports [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 975-977. |
[15] | SHEN Yanjie, WU Yiqing. Management of adverse events during clinical trials [J]. Chinese Journal of Pharmacovigilance, 2023, 20(9): 982-986. |
Viewed | ||||||
Full text |
|
|||||
Abstract |
|
|||||